No difference of opinion with Ayush ministry, says Ramdev’s Patanjali

By: |
Published: July 2, 2020 3:30 AM

The ministry, in a letter to Patanjali, said: “It may be ensured that on the package and label displayed on the medicines, no claim for the cure of Covid-19 should be mentioned.”

Patanjali said, according to the Ayush ministry, the company was now allowed to manufacture and distribute its Divya Coronil tablet, Swasari Vati and Anu Taila across India, in accordance with the manufacturing licences granted by the Uttarakhand government’s State Licensing Authority, Ayurvedic and Unani services.Patanjali said, according to the Ayush ministry, the company was now allowed to manufacture and distribute its Divya Coronil tablet, Swasari Vati and Anu Taila across India, in accordance with the manufacturing licences granted by the Uttarakhand government’s State Licensing Authority, Ayurvedic and Unani services.

Patanjali Ayurved on Wednesday said as directed, it had shared all its clinical trial documents with the Ministry of Ayush, refuting claims of a difference of opinion with the ministry.

“The ministry has also categorically agreed that Patanjali Research Foundation has appropriately worked on Covid-19 management,” the company said in a statement.

Patanjali said, according to the Ayush ministry, the company was now allowed to manufacture and distribute its Divya Coronil tablet, Swasari Vati and Anu Taila across India, in accordance with the manufacturing licences granted by the Uttarakhand government’s State Licensing Authority, Ayurvedic and Unani services.

The announcement by the company comes a day after the Ayush ministry observed that the proposed drug, Divya Coronil tablet, was registered by the State Licensing Authority, Uttarakhand, for use as “immunity booster especially against respiratory tract involvement and all types of fever”.

The ministry, in a letter to Patanjali, said: “It may be ensured that on the package and label displayed on the medicines, no claim for the cure of Covid-19 should be mentioned.” The letter has been reviewed by FE.

Changing tack, a day earlier, MD Acharya Balkrishna had said the firm never claimed its medicines could cure or control coronavirus. “We said that we had made medicines and used them in clinical controlled trial, which cured corona patients. There is no confusion in it,” news agency ANI reported quoting the MD.

Last week, Patanjali had launched the pack of Ayurvedic medicines, claiming that they have a proven efficacy in curing the novel coronavirus, only to stop publicising such claims after the Ayush ministry directed the firm to stop advertising till the issue was duly examined.

Patanjali had been asked to provide details of the name and composition of the medicines being claimed for Covid treatment; sites/hospitals where the research study was conducted for Covid-19; protocol followed, sample size used, Institutional Ethics Committee clearance, CTRI’s registration and results data of the studies.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Bandhan Bank aims to expand home loan portfolio in states having housing shortage
2Modi Government’s Rs 21 lakh crore stimulus brings relief to firms; slows pace of credit downgrades
3Sundaram Finance Q1 net up 6% to Rs 166 crore